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Abstract Mcl-1 is an anti-apoptotic member of the Bcl-2 family
of proteins. We have expressed full length and mutated
GFP:Mcl-1 fusion proteins to define structural motifs that
control protein localisation and stability. When expressed in
U-937 cells, full length Mcl-1 locates primarily within mitochon-
dria and its half-life was approximately 3 h, which was identical
to the native, endogenously expressed protein. When the terminal
20 amino acids from the C-terminus of the protein were detected,
the protein was diffused in the cytoplasm, but its stability was
unaffected. This confirms that this region is responsible for
efficient targeting to mitochondria. Surprisingly, deletion of 104
amino acids (residues 79^183) that contain putative PEST
sequences and other stability regulating motifs, did not affect
protein stability. ß 2000 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
The Bcl-2 family of proteins plays a central role in the
regulation of apoptosis in various cells and tissues [1^3].
Some members of this family protect against apoptosis
(such as Bcl-2 itself, Bcl-XL, A1(B£-1) and Mcl-1) whereas
others promote apoptosis (e.g. Bax, Bcl-XS, Bad, Bid, Bim
and Bak). The functions of these molecules appear to be de-
termined by conserved amino acid sequences within the pro-
teins that are termed BH (Bcl-2 homology) domains [4,5]. The
anti-apoptotic family members contain three or four BH do-
mains (BH1^4) with the BH4 domain found in most anti-ap-
optotic family members with the exception of Mcl-1 and A1
[6^9]. This BH4 domain is reported to be essential for the
anti-apoptotic actions of Bcl-2 and Bcl-XL. Some pro-apopto-
tic family members possess three domains, but some, the so-
called ‘BH3-only’ proteins contain only one of these (BH3),
indicating that this may be an essential death-promoting do-
main [10,11]. In the anti-apoptotic proteins, BH1^3 form a
hydrophobic cleft and it may be that BH3 only proteins
bind this cleft [12].
Mcl-1 was originally cloned as an early induction gene from
the haematopoietic cell line ML-1, following induction of dif-
ferentiation by phorbol ester [13]. Analysis of the predicted
amino acid sequences encoded by this cDNA identi¢ed BH1^
3 domains and a putative hydrophobic transmembrane (TM)
domain likely to be important in membrane anchoring of the
protein (Fig. 1A). There is good evidence to show that Mcl-1,
like Bcl-2 and Bcl-XL, can function as a survival protein as its
over-expression following transfection confers temporary re-
sistance to apoptosis in cell lines or in transgenic mice [14^16].
However, Mcl-1 (40/42 kDa) is a much larger protein than
Bcl-2 (26 kDa) or Bcl-XL (29 kDa), mainly due to the pres-
ence of amino acid stretches towards the N-terminal region of
the protein, than are believed to be important for its unique
properties [17]. The N-terminal region of the protein contains
PEST sequences and Arg:Arg motifs that are commonly
found in proteins with a high rate of turnover [18]. Thus,
Mcl-1 is predicted to have a high turnover rate [13,19]. Fur-
thermore, the carboxy region of the protein is rich in hydro-
phobic amino acids and this region is predicted to serve as a
transmembrane anchor. This region is again di¡erent to that
of Bcl-2 implying that the proteins may insert into di¡erent
membranes. In addition to its high turnover rate, Mcl-1 ex-
pression can be rapidly induced in a variety of cell types (e.g.
[13,20^22], indicating that cellular levels can be rapidly up- or
down-regulated. Thus whilst Mcl-1 can perform a similar
function to Bcl-2 in protection from apoptosis, it expression
is independently regulated and it may be more important than
Bcl-2 in certain cells and tissues at di¡erent stages in their
di¡erentiation programme [23]. For example, Mcl-1 is rapidly
and transiently induced (whilst Bcl-2 levels decrease) in mye-
loid cells during DNA damage [24], and during B cell develop-
ment Mcl-1 expression is transiently induced prior to induc-
tion of Bcl-2 expression [25]. Human neutrophils do not
express Bcl-2 (nor Bcl-XL), but do express Mcl-1, and levels
of expression of this protein correlate with survival of these
cells in response to agents such as GM-CSF and LPS [21].
Antisense disruption of Mcl-1 induces apoptosis in PMA-
treated U-937 cells [26] and in human neutrophils (unpub-
lished observation). A recently reported alternatively spliced
variant of Mcl-1 that has lost its BH1 and BH2 domains to
become a ‘BH3-only’ molecule, can induce apoptosis [27].
Previous work using immuno-cytochemistry has localised
Mcl-1 protein to light intracellular membranes, including mi-
tochondria [19], and there is some evidence to suggest that
even in cells co-expressing Bcl-2 and Mcl-1, these two proteins
may be located at di¡erent sub-cellular sites [28]. In the
present studies we have expressed Mcl-1 as green £uorescent
protein (GFP) fusion proteins in order to determine its sub-
cellular localisation by non-invasive £uorescence imaging. We
have also expressed mutant forms of GFP:Mcl-1 fusion pro-
teins that have deleted TM domains and deleted PEST se-
quences and determined the e¡ects of these mutations on pro-
tein targeting and stability. Full length Mcl-1 was localised to
mitochondria whereas a mutant lacking the TM domain was
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located di¡usely throughout the cytoplasm. Surprisingly, a
mutant with deleted PEST sequences had the same short
half life (approximately 3 h) as native Mcl-1. Thus, other,
as yet unidenti¢able, factors contribute to the instability of
this highly labile protein.
2. Materials and methods
2.1. Materials
pEGFP-C3 Vector and anti-GFP peptide antibodies were from
Clontech. pBluescript KS Vector and XL1-Blue cells were obtained
from Stratagene Ltd. Mcl-1 antiserum was from Pharmingen. Anti-
rabbit IgG-HRP secondary antibody, ECL detection reagent and Hy-
per¢lm ECL were all from Amersham. All restriction, ampli¢cation,
modi¢cation enzymes and the High Pure PCR Product Puri¢cation
kit were from Boehringer Mannheim. RPMI 1640 was from ICN
Biomedicals Ltd, foetal calf serum (FCS) was from Gibco BRL. Mi-
totracker Red CMXRos was from Molecular Probes Europe B.V. All
other specialist materials were from Sigma. Oligonucleotide primers
were synthesised by MWG-Biotech Ltd.
2.2. Cell lines and cell culture
The U-937 human monocytic cell line was obtained from the Euro-
pean Collection of Cell Cultures (ECACC, Salisbury, UK) and cul-
tured at 37‡C under 5% CO2 in RPMI 1640 supplemented with 10%
FCS and 1 mM L-glutamine. Cells were fed 16^20 h prior to the
transfection experiments.
2.3. Reverse transcription and PCR ampli¢cation of the coding region
of the human mcl-1 gene
Human mcl-1 cDNA encompassing the entire coding region
(V1100 bp) was synthesised by reverse transcription and PCR ampli-
¢cation of total RNA isolated from 3 h PMA-stimulated U-937 cells
using two gene speci¢c primers [22]. A sense primer, containing a
HindIII site at its 5P-end (5P-GATAAGCTTCGACTGGCAATG-
TTTGGC-3P) and an antisense primer, containing a BamHI site at
its 5P-end (5P-AATGGATCCTCTTGCCACTTGCTTTTCTG-3P) were
used. 5 Wg total RNA was reverse transcribed with 2.5 Wg antisense
primer. The cDNA was then ampli¢ed by 35 cycles of PCR (denatur-
ing temperature 94‡C, annealing temperature 54‡C, ampli¢cation at
72‡C). 500 ng of the pEGFP-C3 vector and PCR product were re-
stricted by HindIII/BamHI. The restricted vector and the PCR prod-
ucts were gel-puri¢ed, ligated and cloned. The cDNA insert was se-
quenced to verify its identity and absence of mutation. pEGFP-
C3(Mcl-1) was used for transfection and localisation of the fusion
protein. Fusion of Mcl-1 to the C-terminus of GFP ensured that
the putative TM domain of Mcl-1 was free to insert into its target
membrane(s).
2.4. Creation of pEGFP-C3(Mcl-1[vTM]) and
pEGFP-C3(Mcl-1[vPEST]) clones
pEGFP-C3(Mcl-1[vTM]) was prepared by deleting the TM domain
(Fig. 1A) from pEGFP-C3(Mcl-1)). A sense primer, was used for
ampli¢cation of the coding region, (5P-GATAAGCTTCGACTGG-
CAATGTTTGGC-3P) and an antisense primer which by-passed the
TM domain, creating a new stop codon and containing a BamHI site
at its 5P-end (5P-CTGATGGATCCTTATAGGTCCTCTAC-3P) was
used to amplify the coding region minus the TM domain [13,22].
The PCR product was cloned into pEGFP-C3 between the HindIII
and BamHI sites. pEGFP-C3(Mcl-1[vTM]) was used for transfection
and localisation of the fusion protein. pEGFP-C3(Mcl-1[vPEST]) was
prepared by deleting a region containing PEST motifs (Fig. 1A).
Brie£y, the pEGFP-C3(Mcl-1) was restricted with NotI/Asp718 and
cohesive ends produced were blunt ended. The blunt-ended fragment
was gel-puri¢ed and self-ligated. These steps created a new clone,
pEGFP-C3(Mcl-1[vPEST]) which did not contain the PEST motifs
and did not change the reading frame of the downstream coding
region. Successful ampli¢cation of both products was con¢rmed by
sequencing.
2.5. Transient transfection of the fusion protein constructs
Logarithmically growing U-937 cells were resuspended in RPMI
1640 supplemented with 10% FCS and 1 mM L-glutamine at a con-
centration of 1U107 cells/800 Wl and at least 40 Wg of each construct
DNA was added. Cells were electroporated with a single pulse from a
Bio-Rad gene pulser apparatus with a capacitance extender unit
(250 V, 960 WF). Transfected cells were incubated on ice for at least
10 min before and after transfection, and then resuspended in 20 ml of
RPMI 1640 supplemented with 10% FCS and 1 mM L-glutamine.
Transfected cells were incubated in 24-well plates.
2.6. Western blotting
Following transfection, cells were incubated for 40 h at 37‡C in 5%
CO2. The cells were then treated with 10 Wg/ml cycloheximide to
inhibit protein synthesis and incubated for the indicated times. Whole
cell extracts were prepared by resuspending 6U105 cell aliquots each
in 100 Wl SDS^PAGE reducing sample bu¡er and boiled for 5 min.
These extracts were separated by SDS^PAGE using 10% acrylamide
with 2U105 cell equivalents loaded per lane. Following electrophore-
sis, proteins were transferred to PVDF membranes using a Bio-Rad
Mini Protean II Transfer apparatus. The membranes were incubated
with primary antibodies (anti-Mcl-1 primary antibody (1:2000) and
(1 Wg/ml) anti-GFP peptide antibody) overnight at 4‡C. The mem-
branes were then washed for 2U30 s and 3U5 min in wash bu¡er
Fig. 1. Subcellular localisation of GFP:Mcl-1 fusion proteins. A:
Shows the structure of the Mcl-1 protein with putative PEST re-
gions, BH domains and putative TM domains. Numbers refer to
amino acid residues. U-937 cells were transfected with plasmids en-
coding (B) full length GFP:Mcl-1; (C) GFP:Mcl-1 (vTM); (D)
GFP:Mcl-1 (vPEST) or (E) GFP alone. After 40 h incubation cells
were stained for 30 min with 20 ng/ml Mitotracker Red CMXRos
and viewed for red and green £uorescence by confocal microscopy.
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before incubation with HRP-linked rabbit secondary antibody for 1 h
at room temperature. Signals were developed using Amersham’s ECL
detection reagent. Images were captured by using a Hamamatsu XC-
77CE CCD camera and processed using Image 1.44 VDM software.
2.7. Confocal microscopy
After 40 h incubation, transfected cells were prepared for micros-
copy by incubation with 20 ng/ml of a mitochondria-speci¢c dye,
Mitotracker Red CMXRos, for 30 min in cell culture medium. After
mitochondrial staining the cells were washed twice with and then
suspended in PBS pH 7.4. Resuspended cells were placed on micro-
scope slide and images were collected on an LSM 510 confocal micro-
scope. The 488- and 568-nm lines of krypton^argon laser were used
for £uorescent excitation of GFP and Mitotracker Red CMXRos,
respectively.
3. Results and discussion
3.1. Localisation of full length and mutant GFP:Mcl-1 fusion
proteins
Expression of full length Mcl-1 fused to the C-terminus of
GFP, was predicted not to a¡ect the TM domain of the pro-
tein and hence its membrane-binding properties. Mitochon-
dria of U-937 cells stained with Mitotracker as red structures
threaded through the cytoplasm. Full length GFP:Mcl-1 fu-
sion protein clearly co-localised with these mitochondria (Fig.
1B). Similarly, GFP:Mcl-1 (vPEST) fusion protein also co-
localised with mitochondria, indicating that these deleted re-
gions of the protein do not play any role in protein targeting
to membranes (Fig. 1C). However, GFP:Mcl-1 (vTM) fusion
protein did not localise with mitochondria and clearly dis-
played di¡use cytoplasmic staining (Fig. 1D) as did native
GFP (Fig. 1E). These experiments thus con¢rm that (a) full
length Mcl-1 protein localises primarily to mitochondria and
(b) the putative TM domain identi¢ed by consensus structural
motifs in the predicted amino acid sequence of the cDNA [13]
is genuinely responsible for protein targeting to these mito-
chondria.
3.2. Stability of native and GFP fusion proteins
U-937 cells transfected to express full length GPF:Mcl-1
fusion protein were incubated for 40 h and then incubated
with 10 Wg/ml cycloheximide to inhibit de novo protein bio-
synthesis. At timed intervals samples were removed for anal-
ysis of Mcl-1 protein levels (both GFP:Mcl-1 fusion protein
and native, endogenously expressed Mcl-1 protein) by immu-
noblotting. Fig. 2A shows that the full length GFP:Mcl-1
fusion protein ran as a major 65-kDa band, corresponding
to the predicted size of the fusion protein. Also seen in Fig.
Fig. 2. Expression and stability of full length GFP:Mcl-1 fusion
proteins. U-937 cells were transfected with a plasmid encoding a full
length GFP:Mcl-1 fusion protein. After 40 h incubation, cells were
incubated with 10 Wg/ml cycloheximide to inhibit protein synthesis
and then incubated for a further 24 h. At time intervals, aliquots
were removed for immuno-blot analysis using anti-Mcl-1 antibodies.
After immuno-staining, ¢lters were stained with Ponceau red for vis-
ualisation of the actin signal. A: Shows immuno-blot analyses whilst
B shows quantitation of the immuno-blot signals of both the
GFP:Mcl-1 fusion protein (65 kDa) and native, endogenously ex-
pressed Mcl-1 protein (40 kDa). Representative results from three
separate experiments.
Fig. 3. Expression and stability of GFP:Mcl-1 (vTM) fusion pro-
teins. Experimental details are as in the legend to Fig. 2 except that
cells were transfected with a plasmid encoding GFP:Mcl-1 (vTM).
Representative result from three separate experiments.
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2 is endogenously expressed Mcl-1 running at approximately
40 kDa. After addition of cycloheximide, levels of both the
Mcl-1 fusion protein and native Mcl-1 were seen to rapidly
decline such that by 24-h incubation, only very weak signals
were detected by immuno-blotting. This contrasts the levels of
actin protein, which were relatively constant for the duration
of the experiment. Densitometric analysis of these immuno-
blots revealed that the half lives of both the full length
GFP:Mcl-1 fusion protein and native Mcl-1 were virtually
identical, at around 3 h (Fig. 2B). These experiments thus
con¢rm the predicted short half life of both the expressed
and native proteins.
Immunoblotting revealed that the major band seen in cells
expressing the GFP:Mcl-1 (vTM) fusion protein was 62 kDa,
con¢rming that the protein was approximately 3 kDa smaller
than the full length protein due to the deletion of its putative
TM domain (Fig. 3A). The half life of this protein was again
remarkably similar to that of the native Mcl-1 protein, being
approximately 3 h (Fig. 3B). Thus, whilst this mutated protein
does not target e⁄ciently to mitochondria (Fig. 1B), this lack
of targeting neither increases nor decreases its stability. There-
fore, the stability of Mcl-1 does no appear to be a¡ected by its
location within the cell. The expressed GFP:Mcl-1 (vPEST)
fusion protein ran as a band of approximately 54 kDa (close
to the predicted size of this mutant protein) and this protein
was detected by immunoblotting using an antibody raised
against GFP (Fig. 4A). This detection system was necessary
because the antibody used to detect Mcl-1 was raised against
a peptide corresponding to a region contained within this
deleted PEST region of the mutant protein. Cells expressing
native GFP protein showed a major band of approximately 27
kDa, corresponding to the known size of this protein. Re-
markably, the half life of this GFP:Mcl-1 (vPEST) fusion
protein was identical to that of either full length GFP:Mcl-1
or native Mcl-1, being approximately 3 h (Fig. 4B). In order
to exclude the possibility that all proteins derived from this
expression system had equally low stabilities, native GFP was
expressed and its stability assessed. Fig. 5 shows that the
stability of GFP in this experimental system was s 24 h,
indicating that the results seen in Figs. 2^4 were likely to be
due to the inherent biological properties of the full length and
mutant proteins.
In conclusion, we have shown that Mcl-1 protein is located
mainly within the mitochondria of U-937 cells. The approach
that we have used to reach this conclusion is based on expres-
sion of GFP fusion proteins, which has numerous advantages
over techniques such as immuno-cytochemistry which involve
¢xation and permeabilisation of cells. Such techniques can
often lead to artefacts in localisation due to non-speci¢c anti-
body staining and/or redistribution of proteins during the ¢x-
ation/permeabilisation procedures. We have also con¢rmed
that the C-terminal domain of approximately 20 amino acids
is indeed responsible for targeting the protein to mitochon-
dria. However, deletion of some 104 amino acids containing
putative PEST sequences does not increase the normally short
half life of this protein. Clearly, factors outside of this region
of the protein also play important roles in determining the
stability of this short-lived protein.
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